




下載本文檔
版權(quán)說(shuō)明:本文檔由用戶(hù)提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)
文檔簡(jiǎn)介
Hotline:400-820-3792Inhibitors?Agonists?ScreeningLibrarieswww.MedChemEGW5074Cat.No.:HY-10542CASNo.:220904-83-6分?式:C??H?Br?INO?分?量:520.94作?靶點(diǎn):Raf;Apoptosis作?通路:MAPK/ERKPathway;Apoptosis儲(chǔ)存?式:Powder-20°C3years4°C2yearsInsolvent-80°C6months-20°C1month溶解性數(shù)據(jù)體外實(shí)驗(yàn)DMSO:≥100mg/mL(191.96mM)掃描?維碼,*"≥"meanssoluble,butsaturationunknown.運(yùn)?溶解?案計(jì)算器獲得適合您實(shí)驗(yàn)體系的溶解?案MassSolvent1mg5mg10mgConcentration制備儲(chǔ)備液1mM1.9196mL9.5980mL19.1961mL5mM0.3839mL1.9196mL3.8392mL10mM0.1920mL0.9598mL1.9196mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲(chǔ)備液,并請(qǐng)注意儲(chǔ)備液的保存?式和期限。體內(nèi)實(shí)驗(yàn)請(qǐng)根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥?式選擇適當(dāng)?shù)娜芙?案。以下溶解?案都請(qǐng)先按照InVitro?式配制澄的儲(chǔ)備液,再依次添加助溶劑:為保證實(shí)驗(yàn)結(jié)果的可靠性,澄的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件,適當(dāng)保存;體內(nèi)實(shí)驗(yàn)的?作液,建議您現(xiàn)?現(xiàn)配,當(dāng)天使?;以下溶劑前顯?的百分?指該溶劑在您配制終溶液中的體積占?;如在配制過(guò)程中出現(xiàn)沉淀、析出現(xiàn)象,可以通過(guò)加熱和/或超聲的?式助溶1.請(qǐng)依序添加每種溶劑:10%DMSO40%PEG3005%Tween-8045%salineSolubility:≥2.5mg/mL(4.80mM);Clearsolution此?案可獲得≥2.5mg/mL(4.80mM,飽和度未知)的澄溶液。以1mL?作液為例,取100μL25.0mg/mL的澄DMSO儲(chǔ)備液加到400μLPEG300中,混合均勻;向上述1/4www.MedChemEwww.MedChemE體系中加?50μLTween-80,混合均勻;然后繼續(xù)加?450μL?理鹽?定容?1mL。BIOLOGICALACTIVITY?物活性GW5074?種有效的,選擇性的c-Raf抑制劑,IC50值為9nM;對(duì)JNK1/2/3,MEK1,MKK6/7,CDK1/2,c-Src,p38MAP,VEGFR2或c-Fms等沒(méi)有作?。IC50&Targetc-Raf9nM(IC50)體外研究GW5074isapotentandspecificinhibitorofc-RafwithIC50of9nMandhasnoeffectofMKK6,MKK7,p38MAPkinaseandcdksinvitro.However,treatmentofneuronalcultureswithGW5074permitsaccumulationofactivatingmodificationsonc-RafandalsoB-Raf.TheinhibitionofLK-inducedapoptosisbyGW5074incerebellargranuleneuronsisnotMEK-ERK-dependent.GW5074delaysdown-regulationofAktactivitybutinhibitsapoptosisbyanAkt-independentmechanism.GW5074affectsRas,nuclearfactor-kappaBandc-jun.GW5074inhibitscelldeathcausedbyneurotoxinsingranulecellsandotherneuronaltypes[1].體內(nèi)研究GW5074(5mg/Kg)completelypreventsextensivebilateralstriatallesionsinducedby3-NPinmice[1].GW5074suppressessidestreamsmoke-inducedairwayhyperresponsivenessinmice[2].PROTOCOLKinaseAssay[1]Briefly,foreachassay5-10mUofpurifiedkinaseisused.ForGSK3β,cdk1,cdk2,cdk3,cdk5,thekinaseisincubatedwith1μMGW5074inabuffercontaining8mMMOPS,pH7.2,0.2mMEDTA,10mMmagnesiumacetateand[c-33P-ATP]for40minatroomtemperature.Kinaseactivityisquantifiedbymeasuring33PincorporationbyspottinganaliquotonP30filters,washingin50mMphosphoricacidandscintillationcounting.Thebuffercompositionforc-Raf,JNK1,JNK2,JNK3,MEK1,MKK6,MKK7is50mMTrispH7.5,0.1mMEGTA,10mMmagnesiumacetateand[c-33P-ATP].Thepeptidesubstratesusedareasfollows:Forc-Raf,0.66mg/mLMBP;forcdks,0.1mg/mLhistoneH1;forJNKs,3μMATF2;forMEK1,1μMMAPK2;forMKK6,1μMofSAPK2aandforMKK7,2μMJNK1α.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.CellAssay[1]Befiy,thetetrazoliumsaltMTTisaddedtotheculturesatafinalconcentrationof1mg/mL,andincubationofthecultureiscontinuedintheCO2incubatorforaHirther30minat37°C.Theassayisstoppedbyaddinglysisbuffer[20%sodiumdodecyisulfate(SDS)in50%N,N-dimethylformamide,pH4.7],Theabsorbanceismeasuredspectrophotometricallyat570nmafteranovemightincubationatroomtemperature.Theabsorbanceofawellwithoutcellsisusedasbackgroundandsubtracted.Dataarepresentedasmean±standarddeviation.StatisticalanalysisisperfomiedusingANOVAandStudent-Neuman-Keuls'test.BesidesMTTassays,viabilityisalsoquantitiedusingthetluorescein-diacetatemethodandbyDAPIstaining(whichrevealsapoptoticnucleiascondensedorfragmented).TheresultsusingtheseassaysaresimilartothoseobtainedwiththeMTTassay.MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.2/4www.MedChemEwww.MedChemEAnimalTheTru-Scan?activitymonitoringsystemisusedtoassesslocomotoractivityonmiceonthedayfollowingAdministration[1]the5daysofinjectionwithsaline,3-NPoracombinationof3-NPandGW5074(7animalsineachgroup).TheanimalisplacedinaPerspexarena(25.9×25.9cm)witbinfraredbeamsspacedat0.6-inchintervalsintheX-Yplane.ThearenaisalsoequippedwithasecondinfraredbeamsystemattheZplanepositioned2.54cmabovetheX-Yplane.Inthissystemthemovementoftheanimalisaccuratelyassessedbyinterruptionsin17×17-gridsystemcreatedbytheinfraredbeamsinboththeX-YandZplanes.Theanimalisallowedtoremaininthearenafor15min,withdatacollectionperformedduringthisperiodusingtheTruScanLineinterfaceboxandTmScan99software,operatingthroughaPentiumPC.Thefollowingbehavioralparametersareselected:(i)Totalmovementsepisodes:eachmovementintheflorplaneisaseriesofcoordinatechangeswithnorestforatleastIsampleinterval;(ii)totalmovementdistance:thesumofallvectoredA-Ycoordinatechangesinthefloorplane;(iii)meanvelocity:themeanvelocityofallX-Ycoordinatechangedefinedmovements;and(iv)verticalplaneentries:thetotalnumberoftimesanypartoftheanimalenteredtheverticalplane(Zplane).MCEhasnotindependentlyconfirmedtheaccuracyofthesemethods.Theyareforreferenceonly.戶(hù)使?本產(chǎn)品發(fā)表的科研?獻(xiàn)?BiochemJ.2019Mar12;476(5):875-887.?SciRep.2020Jul7;10(1):11158.?AnnTranslMed.2019Dec;7(23):758.?HarvardMedicalSchoolLINCSLIBRARYSeemorecustomervalidationsonwww.MedChemEREFERENCES[1].ChinPC,etal.Thec-RafinhibitorGW5074providesn
溫馨提示
- 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
- 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶(hù)所有。
- 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
- 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
- 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶(hù)上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶(hù)上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
- 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
- 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶(hù)因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。
最新文檔
- 航空運(yùn)輸合同書(shū)
- 公司內(nèi)部銷(xiāo)售承包合同
- 土地買(mǎi)賣(mài)居間服務(wù)合同
- 返聘勞務(wù)合同
- 工程建設(shè)項(xiàng)目委托招標(biāo)代理合同
- 舊機(jī)動(dòng)車(chē)交易合同書(shū)
- 影視制作服務(wù)版權(quán)轉(zhuǎn)讓合同
- 山東特殊教育職業(yè)學(xué)院《口腔解剖生理學(xué)一》2023-2024學(xué)年第二學(xué)期期末試卷
- 山西工商學(xué)院《機(jī)器人學(xué)導(dǎo)論》2023-2024學(xué)年第二學(xué)期期末試卷
- 山東勞動(dòng)職業(yè)技術(shù)學(xué)院《模具設(shè)計(jì)》2023-2024學(xué)年第二學(xué)期期末試卷
- 2024年06月日照銀行社會(huì)招聘筆試歷年參考題庫(kù)附帶答案詳解
- 醫(yī)院培訓(xùn)課件:《靜脈采血法并發(fā)癥的預(yù)防及處理》
- 《修繕學(xué)習(xí)交底資料》課件
- 2024-2025學(xué)年高二上學(xué)期期末復(fù)習(xí)解答題壓軸題十七大題型專(zhuān)練(范圍:第四、五章)(含答案)
- 單層鋼結(jié)構(gòu)工業(yè)廠房施施工組織設(shè)計(jì)
- 投資公司組織架構(gòu)和運(yùn)作流程
- 筑牢安全防線共創(chuàng)平安校園
- 2024年大學(xué)生電子版三方協(xié)議書(shū)模板
- GB/T 44619-2024福壽螺檢疫鑒定方法
- 2024年湖南省公務(wù)員錄用考試《行測(cè)》試題及答案解析
- 電力工程質(zhì)量驗(yàn)收手冊(cè)
評(píng)論
0/150
提交評(píng)論